We thank Dr Schneider for his comments on our report.1 We share his enthusiasm for “well-conducted and methodologically sound randomized controlled trials.”2 However, we do not agree that “as physicians, we should be comfortable prescribing medication for longer periods of time than the length of the randomized trials” based on the evidence from the shorter-term randomized trials and “patients' preferences.” We believe that this prescribing comfort should be informed, to the extent possible, by the best available evidence.
Reisberg B, Doody R, Schmitt F, Ferris S. Open-Label Extension Studies and Misinformation—Reply. Arch Neurol. 2006;63(7):1036–1037. doi:10.1001/archneur.63.7.1036-b
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: